No abstract

No abstract

No abstract

Leprosy Research Un i!, Na tional Leprosy Contra i Ce ntre.Sungei Euloh, Selangor. Ma laysia A double-blind, intemally-controlled clinicaI tr ial is reported of th e effect of dapsone on the severity of erythema nodosum leprosum (EN L) in 17 sulphone resistant lepromatous patients , 16 of whom were suffering from ENL of varying severity . During th e 10 weeks of th e trial, altemative anti-Ieprosy tr eatment was continued unchanged. Dapsone, 100 mg daily in a c.oloured ca psule, was prescribed fo r 14 consecutive days between the th ird and seventh weeks, th e timing being allocated by random distribution, and on th e remaining 56 days an identical placebo capsule was given. The clinicaI severity of the ENL was measured by a number of parameters , and th e intake of ali reaction-suppressing drugs was recorded. No evidence was obtained th at dapsone either immed iately or after an interval, exacerbated or precipitated episodes of ENL. It is concluded that dapsone has no direct ENL-stimulating action per se , but th at ENL results indirect1y , consequent on the drug's chemotherapeutic activity against Mycoba cteri um lepra e.

Nine patients suffering fro m persistent, moderately severe ery/hema nodosum leprosum (ENL) were included in this study. During a period of 8 or 10 weeks when anti-leprosy treatment with dapsone was replaced by a placebo capsule, there was a fall in the severity of the ENL wh.ich just attained statist ical significance. When dapsone treatment was restarted in full dosage (100 mg daily), using a capsule identical to the placebo, there was no effect on the ENL for the first 2 weeks, and a slight (but statistically insignificant) increase in its severity thereafter. Erythema nodosum leprosum (ENL) was first recognized, and indeed named. long